Literature DB >> 17497897

Time-dependent inactivation of P450 3A4 by raloxifene: identification of Cys239 as the site of apoprotein alkylation.

Brian R Baer1, Larry C Wienkers, Dan A Rock.   

Abstract

Time-dependent inactivation of cytochrome P450s is typically a result of substrate bioactivation to form reactive species that subsequently alkylate the heme group, apoprotein, or both. The chemical identity of many reactive intermediates is generally proposed based on the products of trapping reactions with nucleophilic agents as only a few P450-drug adducts have been directly characterized. We describe the use of mass spectrometry to show that a single equivalent of raloxifene is bound to the intact P450 apoprotein. Furthermore, mass analysis of peptides following digestion with proteinase K revealed that the covalently bound drug is localized to residue Cys239. A mass shift of 471 Da to the intact protein and peptide, relative to control samples, indicated that time-dependent inactivation of P450 3A4 occurred through the raloxifene diquinone methide intermediately prior to nucleophilic attack of the sulfur of Cys239. Association between raloxifene adduction to P450 3A4 apoprotein and the observed time-dependent inactivation was further investigated with the use of cysteine-specific modifying reagents. When P450 3A4 was treated with iodoacetamide or N-(1-pyrene)iodoacetamide, which alkylated residue Cys239 exclusively, time-dependent inactivation of P450 3A4 by raloxifene was prevented. The change in protein mass of 471 Da combined with the protection from inactivation that occurred through pre-alkylation of Cys239 provided conclusive evidence that raloxifene-mediated P450 3A4 inactivation occurred through the bioactivation of raloxifene to the diquinone methide and subsequent alkylation of Cys239.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17497897     DOI: 10.1021/tx700037e

Source DB:  PubMed          Journal:  Chem Res Toxicol        ISSN: 0893-228X            Impact factor:   3.739


  19 in total

Review 1.  Human Family 1-4 cytochrome P450 enzymes involved in the metabolic activation of xenobiotic and physiological chemicals: an update.

Authors:  Slobodan P Rendic; F Peter Guengerich
Journal:  Arch Toxicol       Date:  2021-01-18       Impact factor: 5.153

Review 2.  Challenges and Opportunities with Non-CYP Enzymes Aldehyde Oxidase, Carboxylesterase, and UDP-Glucuronosyltransferase: Focus on Reaction Phenotyping and Prediction of Human Clearance.

Authors:  Upendra A Argikar; Philip M Potter; J Matthew Hutzler; Punit H Marathe
Journal:  AAPS J       Date:  2016-08-05       Impact factor: 4.009

3.  Quinone Methide Bioactivation Pathway: Contribution to Toxicity and/or Cytoprotection?

Authors:  Judy L Bolton
Journal:  Curr Org Chem       Date:  2014-01-01       Impact factor: 2.180

4.  Identification of the residue in human CYP3A4 that is covalently modified by bergamottin and the reactive intermediate that contributes to the grapefruit juice effect.

Authors:  Hsia-Lien Lin; Cesar Kenaan; Paul F Hollenberg
Journal:  Drug Metab Dispos       Date:  2012-02-16       Impact factor: 3.922

5.  Improved cytochrome P450 3A4 molecular models accurately predict the Phe215 requirement for raloxifene dehydrogenation selectivity.

Authors:  Chad D Moore; Kiumars Shahrokh; Stephen F Sontum; Thomas E Cheatham; Garold S Yost
Journal:  Biochemistry       Date:  2010-10-19       Impact factor: 3.162

6.  Metabolic intermediate complex formation of human cytochrome P450 3A4 by lapatinib.

Authors:  Hideo Takakusa; Michelle D Wahlin; Chunsheng Zhao; Kelsey L Hanson; Lee Sun New; Eric Chun Yong Chan; Sidney D Nelson
Journal:  Drug Metab Dispos       Date:  2011-03-01       Impact factor: 3.922

7.  High-Level Production and Properties of the Cysteine-Depleted Cytochrome P450 3A4.

Authors:  Irina F Sevrioukova
Journal:  Biochemistry       Date:  2017-06-07       Impact factor: 3.162

8.  Mechanism-based inactivation of human cytochrome P450 3A4 by two piperazine-containing compounds.

Authors:  Amanda K Bolles; Rina Fujiwara; Erran D Briggs; Amin A Nomeir; Laura Lowe Furge
Journal:  Drug Metab Dispos       Date:  2014-10-01       Impact factor: 3.922

9.  Selective estrogen receptor modulator BC-1 activates antioxidant signaling pathway in vitro via formation of reactive metabolites.

Authors:  Bo-lan Yu; Zi-xin Mai; Xu-xiang Liu; Zhao-feng Huang
Journal:  Acta Pharmacol Sin       Date:  2013-01-21       Impact factor: 6.150

10.  CYP3A4-Mediated carbamazepine (CBZ) metabolism: formation of a covalent CBZ-CYP3A4 adduct and alteration of the enzyme kinetic profile.

Authors:  Ping Kang; Mingxiang Liao; Michael R Wester; J Steven Leeder; Robin E Pearce; Maria Almira Correia
Journal:  Drug Metab Dispos       Date:  2007-12-20       Impact factor: 3.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.